Clinical trials
Phase 3 Alzheimer Disease trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
73 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 6 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 7 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 7 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 32 |
| Terminated | 26 |
| Recruiting | 8 |
| Active, not recruiting | 4 |
| Suspended | 1 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 9 |
| Eli Lilly and Company | 7 |
| Pfizer | 6 |
| Biogen | 4 |
| Bristol-Myers Squibb | 4 |
| H. Lundbeck A/S | 3 |
| TauRx Therapeutics Ltd | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| AstraZeneca | 2 |
| Axovant Sciences Ltd. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alzheimer Disease | 73 |
| Dementia | 18 |
| Cognitive Dysfunction | 11 |
| Neurodegenerative Diseases | 7 |
| Brain Diseases | 5 |
| Amyloid Neuropathies, Familial | 4 |
| Mental Disorders | 4 |
| Nervous System Diseases | 4 |
| Psychomotor Agitation | 4 |
| Amyloidosis | 3 |
Trials
Showing 1 to 25 of 73. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.